Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation for the Netherlands based on the LIFE-study

被引：1
|
作者：
Boersma, C
Carides, GW
Burke, TA
Postma, MJ
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Merck Res Labs, Blue Bell, PA USA
[3] Merck & Co Inc, Whitehouse Stn, NJ USA
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67611-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A150 / A151
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness in extracorporeal life support in critically ill adults in the Netherlands
    Lansink-Hartgring, Annemieke Oude
    Miranda, Dinis Dos Reis
    Donker, Dirk W.
    Maas, Jacinta J.
    Delnoij, Thijs
    Kuijpers, Marijn
    van den Brule, Judith
    Scholten, Erik
    Endeman, Hendrik
    Vlaar, Alexander P. J.
    van den Bergh, Walter M.
    BMC HEALTH SERVICES RESEARCH, 2018, 18
  • [32] Cost-effectiveness in extracorporeal life support in critically ill adults in the Netherlands
    Annemieke Oude Lansink-Hartgring
    Dinis Dos Reis Miranda
    Dirk W. Donker
    Jacinta J. Maas
    Thijs Delnoij
    Marijn Kuijpers
    Judith van den Brule
    Erik Scholten
    Hendrik Endeman
    Alexander P. J. Vlaar
    Walter M. van den Bergh
    BMC Health Services Research, 18
  • [33] COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS
    Thurston, S. J.
    Webb, K.
    Ong, S.
    Meerding, W. J.
    van Hout, B. A.
    VALUE IN HEALTH, 2009, 12 (07) : A335 - A335
  • [34] COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN STABLE ANGINA PATIENTS IN THE NETHERLANDS
    Nuijten, M. J.
    Redekop, W. K.
    VALUE IN HEALTH, 2008, 11 (06) : A342 - A343
  • [35] Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation
    Jones, PW
    Wilson, K
    Sondhi, S
    RESPIRATORY MEDICINE, 2003, 97 (01) : 20 - 26
  • [36] An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands
    Boersma, Cornelis
    Carides, George W.
    Atthobari, Jarir
    Voors, Adriaan A.
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2007, 29 (05) : 963 - 971
  • [37] Cost-effectiveness of Community Treatment Orders (CTOs): Economic Evaluation of the OCTET Study
    Simon, Judit
    Gray, Alastair
    Mayer, Susanne
    Laszewska, Agata
    Rugkasa, Jorun
    Yeeles, Ksenija
    Burns, Tom
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2015, 18 : S36 - S36
  • [38] Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial
    Jamieson, Lise
    Serenata, Celicia
    Makhubele, Lebogang
    Sokhela, Simiso
    Mashabane, Nkuli
    Akpomiemie, Godspower
    Johnson, Leigh F.
    Venter, Willem D. F.
    Meyer-Rath, Gesine
    AIDS, 2021, 35 : S173 - S182
  • [39] Economic evaluation of a novel community-based diabetes care model in rural Mexico: a cost and cost-effectiveness study
    Duan, Kevin, I
    Rodriguez Garza, Francisco
    Flores, Hugo
    Palazuelos, Daniel
    Maza, Jimena
    Martinez-Juarez, Luis Alberto
    Elliott, Patrick F.
    Moreno Lazaro, Elena
    Enriquez Rios, Natan
    Nigenda, Gustavo
    Palazuelos, Lindsay
    McBain, Ryan K.
    BMJ OPEN, 2021, 11 (04):
  • [40] Cost-effectiveness of aliskiren added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and nephropathy by age
    Delea, Thomas E.
    Sofrygin, Oleg
    Palmer, James L.
    Annemans, Liev-En
    Lau, Helen
    Munk, Veronica C.
    Sung, Jennifer
    Charney, Alan
    Sullivan, Sean D.
    DIABETES, 2008, 57 : A137 - A137
12345